ArticleJournal of medical biochemistry2025
Correlations of gene polymorphisms of angiotensin-converting enzyme 2 with onset and prognosis of hypertrophic cardiomyopathy.
Article in Journal of medical biochemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: To investigate the correlations of the gene polymorphisms of angiotensin-converting enzyme 2 (ACE2) with the onset and prognosis of hypertrophic cardiomyopathy (HCM), so as to provide references for the early prevention and precise treatment of HCM in the future. Methods: In this case-control study, a total of 100 HCM patients (HCM group) and 100 healthy people receiving physical examination who had matched age, gender and race (Control group) were collected. The single nucleotide polymorphisms (rs102312, rs102883 and rs119247) in the promoter region of ACE2 gene were genotyped by means of conformation-difference gel electrophoresis. Whether the distribution frequency of ACE2 genotypes is in agreement with the law of genetic equilibrium was examined using chi-square test. Meanwhile, the correlations of different polymorphisms and alleles in the promoter region of ACE2 gene with the onset and prognosis of HCM were analyzed. Results: The Hardy-Weinberg equilibrium analysis showed that all the three polymorphisms of ACE2 gene were in agreement with the law of genetic equilibrium (p>0.05). According to the results of genetic association analysis, the polymorphism rs102312 and its alleles in the promoter region of ACE2 gene were correlated with the occurrence of HCM (p<0.05), while the polymorphisms rs102883 and rs119247 as well as their alleles had no associations with the occurrence of HCM (p>0.05). Furthermore, it was found that the cardiac function and prognosis of HCM patients carrying genotype GG of polymorphism rs102312 were poorer than those of patients carrying genotype TT (p<0.05). Conclusions: The polymorphism rs102312 in the promoter region of ACE2 gene is associated with the onset of HCM in patients, and HCM patients carrying the genotype GG of polymorphism rs102312 have a poorer clinical prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.